Results 21 to 30 of about 21,936 (207)
Genotype-Guided Use of P2Y12 Inhibitors: A Review of Current State of the Art
Frontiers in Cardiovascular Medicine, 2022 The pharmacodynamics of the purinergic receptor type Y, subtype 12 (P2Y12) inhibitors has evolved. Our understanding of the metabolism of P2Y12 inhibitors has revealed polymorphisms that impact drug metabolism and antiplatelet efficacy, leading to ...
Abdullah Al-abcha +6 more
doaj +1 more source
Journal of Thrombosis and Haemostasis, 2009 A number of new antiplatelet agents currently in development are anticipated to improve clinical outcomes and safety benefits in patients with acute coronary syndrome (ACS). This article reviews the pharmacology and clinical development of three of these agents: prasugrel, cangrelor, and ticagrelor.
openaire +3 more sources
Platelets, 2018 The release of ADP from platelet dense granules and its binding to platelet P2Y12 receptors is key to amplifying the initial hemostatic response and propagating thrombus formation.
Annachiara Mitrugno +7 more
doaj +1 more source
Characterisation of P2Y(12) receptor responsiveness to cysteinyl leukotrienes.
PLoS ONE, 2013 Leukotriene E4 (LTE4), the most stable of the cysteinyl leukotrienes (cysLTs), binds poorly to classical type 1 and 2 cysLT receptors although in asthmatic individuals it may potently induce bronchial constriction, airway hyperresponsiveness and ...
Holly R Foster +4 more
doaj +1 more source
Behavioural Neurology, 2022 There have been speculation and research linking migraine with abnormalities of platelet aggregation and activation. The role of the P2Y12 platelet inhibitor in the treatment of migraine has not been established.
Fengzhi Wang +4 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Background The ADAPTABLE (Aspirin Dosing: A Patient‐Centric Trial Assessing Benefits and Long‐Term Effectiveness) was a large, pragmatic, randomized controlled trial that found no difference between high‐ versus low‐dose aspirin for secondary prevention ...
Saket Girotra +19 more
doaj +1 more source
Scientific Reports, 2021 P2Y12 blockade improves patient outcomes after myocardial infarction. As well as antithrombotic effects, anti-inflammatory effects may contribute to this beneficial clinical outcome.
Patrick M. Siegel +13 more
doaj +1 more source
Brain CirculationBACKGROUND: When a seizure occurs, the distribution of purine receptors in different cell types at various time points remains poorly understood. Our literature review revealed that P2X7, P2Y6, and P2Y12 are expressed in different cells during epilepsy ...
Yue Li, Fengru Tang, Yumin Luo
doaj +1 more source
Journal of Interventional Cardiology, 2021 Introduction. This network meta-analysis aimed to evaluate the efficacy and safety of different dual antiplatelet therapies (DAPTs) after percutaneous coronary intervention (PCI) with drug-eluting stents (DESs). Methods.
Yi Xu +4 more
doaj +1 more source
P2Y12 Inhibitor Monotherapy: Considerations for Acute and Long-Term Secondary Prevention Post-PCI
Reviews in Cardiovascular Medicine, 2022 Following percutaneous coronary intervention (PCI), an initial course of dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor (P2Y12-i) is recommended to minimize the risk of thrombotic complications.
Antonio Greco +3 more
doaj +1 more source